No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population

Overview

Journal Iran Red Crescent Med J

Specialty General Medicine

Date 2015 Oct 1

PMID 26421175

Authors

Mohammad Reza Eslami Amirabadi

Rozita Davari-Ashtiani

Mojgan Khademi

Sepideh Rajeziesfahani

Babak Emamalizadeh

Abolfazl Movafagh

Fariba Arabgol

Said Sadr

Hossein Darvish

Katayoon Razjouyan

Affiliations

Soon will be listed here.

Abstract

Background: Attention Deficit Hyperactivity Disorder (ADHD) can lead to drastic problems for the patient and its worldwide prevalence is 5%-12%. It also has many comorbidities with other disorders, and the genetic contribution seems the most significant cause.

Objectives: The current study was conducted to investigate the association between norepinephrine transporter-3081 (A/T) polymorphisms and ADHD in Iranian population.

Patients And Methods: Participants were chosen from children and adolescents diagnosed with ADHD referred to Imam Hoseyn Hospital. A child and adolescent psychiatrist confirmed the diagnosis using the Kiddie-Sads-Present and Lifetime Version (K-SADS-PL) semi-structural interview. The control group was from pupils of schools in Tehran (capital city of Iran) who had no history or presence of psychiatric and medical complications. Also, a child and adolescent psychiatrist confirmed their health using the K-SADS-PL semi-structural interview. Genetic examinations were DNA distraction, Polymerase Chain Reaction (PCR), and Restricted Fragment Length Polymorphism (RFLP), which were conducted according to standard protocols. The statistical analysis was performed using chi-square and Fisher's exact test in SPSS version 21.

Results: The percentages of ADHD subtypes for combined, inattentive, and hyperactive/impulsive were 72.2%, 17.2%, and 11.9%, respectively. There was no significant association between norepinephrine transporter polymorphism and ADHD (P = 0.81). Moreover, no significant relationship was found between gender [male (P = 0.92) and female (P = 0.63)] and polymorphism. No significant association was found between subtypes of ADHD [combined (P = 0.46), inattentive (P = 0.41), hyperactive/impulsive (P = 0.32)] and polymorphism SCL6A2. This lack of association can also be seen in gender in every subtype.

Conclusions: The results of the study show no significant association between norepinephrine transporter polymorphism SCL6A2 and ADHD.

References

Rosler M, Retz W, Retz-Junginger P, Hengesch G, Schneider M, Supprian T . Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci. 2004; 254(6):365-71. DOI: 10.1007/s00406-004-0516-z. View

Kim J, Biederman J, McGrath C, Doyle A, Mick E, Fagerness J . Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Mol Psychiatry. 2007; 13(6):624-30. DOI: 10.1038/sj.mp.4002090. View

Retz W, Rosler M, Kissling C, Wiemann S, Hunnerkopf R, Coogan A . Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm (Vienna). 2007; 115(2):323-9. DOI: 10.1007/s00702-007-0822-5. View

Rowland A, Lesesne C, Abramowitz A . The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002; 8(3):162-70. DOI: 10.1002/mrdd.10036. View

Brook U, Boaz M . Attention deficit and hyperactivity disorder (ADHD) and learning disabilities (LD): adolescents perspective. Patient Educ Couns. 2005; 58(2):187-91. DOI: 10.1016/j.pec.2004.08.011. View

Schimmelmann B, Friedel S, Christiansen H, Dempfle A, Hinney A, Hebebrand J . [Genetic findings in Attention-Deficit and Hyperactivity Disorder (ADHD)]. Z Kinder Jugendpsychiatr Psychother. 2006; 34(6):425-33. DOI: 10.1024/1422-4917.34.6.425. View

Nikolas M, Burt S . Genetic and environmental influences on ADHD symptom dimensions of inattention and hyperactivity: a meta-analysis. J Abnorm Psychol. 2010; 119(1):1-17. DOI: 10.1037/a0018010. View

Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J . Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl). 2006; 188(1):119-27. DOI: 10.1007/s00213-006-0483-3. View

Faraone S, Perlis R, Doyle A, Smoller J, Goralnick J, Holmgren M . Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57(11):1313-23. DOI: 10.1016/j.biopsych.2004.11.024. View

10.

Lasky-Su J, Neale B, Franke B, Anney R, Zhou K, Maller J . Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(8):1345-54. DOI: 10.1002/ajmg.b.30867. View

11.

McEvoy B, Hawi Z, Fitzgerald M, Gill M . No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. Am J Med Genet. 2002; 114(6):665-6. DOI: 10.1002/ajmg.10416. View

12.

Joung Y, Kim C, Moon J, Jang W, Yang J, Shin D . Association studies of -3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population. Am J Med Genet B Neuropsychiatr Genet. 2009; 153B(2):691-694. DOI: 10.1002/ajmg.b.31012. View

13.

Biederman J, Kim J, Doyle A, Mick E, Fagerness J, Smoller J . Sexually dimorphic effects of four genes (COMT, SLC6A2, MAOA, SLC6A4) in genetic associations of ADHD: a preliminary study. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(8):1511-8. PMC: 2587524. DOI: 10.1002/ajmg.b.30874. View

14.

Barr C, Kroft J, Feng Y, Wigg K, Roberts W, Malone M . The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am J Med Genet. 2002; 114(3):255-9. DOI: 10.1002/ajmg.10193. View

15.

Albayrak O, Friedel S, Schimmelmann B, Hinney A, Hebebrand J . Genetic aspects in attention-deficit/hyperactivity disorder. J Neural Transm (Vienna). 2008; 115(2):305-15. DOI: 10.1007/s00702-007-0839-9. View

16.

Bobb A, Addington A, Sidransky E, Gornick M, Lerch J, Greenstein D . Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet. 2005; 134B(1):67-72. DOI: 10.1002/ajmg.b.30142. View

17.

Hummer T, Kronenberger W, Wang Y, Dunn D, Mosier K, Kalnin A . Executive functioning characteristics associated with ADHD comorbidity in adolescents with disruptive behavior disorders. J Abnorm Child Psychol. 2010; 39(1):11-9. DOI: 10.1007/s10802-010-9449-3. View

18.

Gamo N, Wang M, Arnsten A . Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010; 49(10):1011-23. PMC: 2999884. DOI: 10.1016/j.jaac.2010.06.015. View

19.

Gizer I, Ficks C, Waldman I . Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009; 126(1):51-90. DOI: 10.1007/s00439-009-0694-x. View

20.

Kim C, Hahn M, Joung Y, Anderson S, Steele A, Mazei-Robinson M . A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2006; 103(50):19164-9. PMC: 1748193. DOI: 10.1073/pnas.0510836103. View